Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Altamira Therapeutics Ltd...

    NASDAQ: CYTO · Real-Time Price · USD
    0.30
    0.00 (0.00%)
    At close: Jan 16, 2025, 10:00 PM

    Altamira Therapeutics Statistics

    Share Statistics

    Altamira Therapeutics has 3.78M shares outstanding. The number of shares has increased by 68.67% in one year.

    Shares Outstanding

    n/a
    		 3.78M

    Shares Change (YoY)

    n/a
    		 68.67%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 3.13%

    Shares Floating

    n/a
    		 2.65M

    Failed to Deliver (FTD) Shares

    n/a
    		 7,891

    FTD / Avg. Volume

    n/a
    		 5.59%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -0.2 and the forward PE ratio is null. Altamira Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.2

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 0.22

    P/FCF Ratio

    n/a
    		 -0.12

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Altamira Therapeutics has an Enterprise Value (EV) of 918.84K.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -0.68

    EV / EBIT

    n/a
    		 -0.08

    EV / FCF

    n/a
    		 -0.08

    Financial Position

    The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 1.38

    Quick Ratio

    n/a
    		 1.38

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.07

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -112.56% and Return on Invested Capital is -85.68%.

    Return on Equity

    n/a
    		 -112.56%

    Return on Assets

    n/a
    		 -94.49%

    Return on Invested Capital

    n/a
    		 -85.68%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-727,003.8

    Employee Count

    n/a
    		 10

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -79.17% in the last 52 weeks. The beta is 2.44, so Altamira Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.44

    52-Week Price Change

    n/a
    		 -79.17%

    50-Day Moving Average

    n/a
    		 0.23

    200-Day Moving Average

    n/a
    		 0.81

    Relative Strength Index (RSI)

    n/a
    		 46.38

    Average Volume (20 Days)

    n/a
    		 141,045

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -5.92M

    Net Income

    n/a
    		 -7.27M

    EBITDA

    n/a
    		 -1.35M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -14.81
    Full Income Statement

    Balance Sheet

    The company has 617.41K in cash and 99.66K in debt, giving a net cash position of 517.75K.

    Cash & Cash Equivalents

    n/a
    		 617.41K

    Total Debt

    n/a
    		 99.66K

    Net Cash

    n/a
    		 517.75K

    Retained Earnings

    n/a
    		 -18.05M

    Total Assets

    n/a
    		 7.69M

    Working Capital

    n/a
    		 334.24K
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -11.51M and capital expenditures 0, giving a free cash flow of -11.51M.

    Operating Cash Flow

    n/a
    		 -11.51M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -11.51M

    FCF Per Share

    n/a
    		 -23.44
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CYTO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -506.06%

    FCF Yield

    n/a
    		 -801.28%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for CYTO.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Dec 13, 2023. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Dec 13, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -3.85

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist